Skip to Main Content

News

Pretzel Therapeutics Announces Publication in Nature unveiling discovery of novel small molecule activators for the treatment of POLG disorders and other conditions related to mtDNA depletion

Pretzel Therapeutics Initiates Phase 1 Clinical Study Evaluating PX578, Lead Therapeutic in its Bioenergetics Restoration Franchise

Pretzel Therapeutics Launches With $72.5 Million Series A Financing to Pioneer Mitochondrial Therapies

September 12, 2022

Press
Releases

News